New gene editing technique offers hope for millions

FHS
July 11, 2024
5:32 am

A team led by Mass Eye and Ear researchers has demonstrated for the first time a successful restoration of hearing through a novel, in vivo genome editing approach in an adult mouse model with a form of inherited deafness caused by mutations in microRNA.

NanoSyrinx to advance development of biologic therapeutics

The investment is aimed at accelerating the development of treatments for intracellular targets. Credit: Gorodenkoff/Shutterstock. Synthetic biology company NanoSyrinx has announced the closure of a

September 11, 2024

‘Underwhelming’: NIH trials fail to test meaningful long Covid treatments — after 2.5 years and $1 billion

More than 2.5 years after the National Institutes of Health received a $1 billion mandate from Congress to study and treat long Covid, the agency

August 9, 2023

Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic

Closed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, and Pharmanovia, a global

May 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.